Comparative Pharmacology
Head-to-head clinical analysis: GVS versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
GVS vs NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Neomycin and polymyxin B sulfates are aminoglycoside and polypeptide antibiotics, respectively, that inhibit bacterial protein synthesis and disrupt bacterial cell membrane integrity. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
Ophthalmic: 1-2 drops in affected eye(s) every 3-4 hours; severe infections: 1-2 drops every 1-2 hours, then taper. Otic: 3-4 drops in affected ear(s) 3-4 times daily.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Neomycin: 2-3 hours (IM/IV, if absorbed); Polymyxin B: 6-7 hours; Dexamethasone: 3-4.5 hours. Clinically, neomycin's half-life is not relevant due to minimal absorption; polymyxin B prolonged in renal impairment; dexamethasone CNS effect lasts > half-life.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Neomycin: ~99% of oral dose eliminated unchanged in feces; <1% absorbed renally excreted. Polymyxin B: ~60% renal elimination of absorbed fraction; remainder non-renal via biliary/fecal. Dexamethasone: ~65% renal as metabolites, <10% unchanged; ~35% fecal.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic